Evommune Closes $50 Million Series B Financing To Advance Broad Pipeline Of Therapies To Treat Chronic Inflammatory Diseases
Amount Raised
$50 Million
Round Type
Series B
Palo AltoBiotechnologyHealth CareInvestors
Description
Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the completion of a $50 million Series B financing. The financing was co-led by new investor Arix Bioscience and current investors EQT Life Sciences and SymBiosis, with participation from new and existing investors including Amplitude Ventures, and Series A leads Pivotal bioVenture Partners and Andera Partners.
Quick answer
Evommune raised $50 Million in a Series B round, dated April 26, 2023. Investors: Andera Partners, Pivotal Bio Venture Partners, Amplitude Ventures, Sym Biosis, EQT Life Sciences and Arix Bioscience. Evommune is based in Palo Alto, California, United States.
- How much did Evommune raise?
- Evommune raised $50 Million in a Series B round on April 26, 2023.
- Who invested in Evommune?
- Andera Partners, Pivotal Bio Venture Partners, Amplitude Ventures, Sym Biosis, EQT Life Sciences and Arix Bioscience are named as investors in this round.
- What does Evommune do?
- Evommune, Inc. is a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases.
- Where is Evommune based and how big is it?
- Evommune is based in Palo Alto, California, United States. Fundz records about 45 employees.
- Who are the decision-makers at Evommune?
- Fundz holds 1 contact at Evommune. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Evommune that raised within 45 days of this round, from Fundz verified event records.
- Avenda Health, Inc. raised $3.5M (Series B) on June 8, 2023.
- Kate Therapeutics raised $51M (Series A) on June 8, 2023.
- Upstream Bio raised $200M (Series B) on June 8, 2023.
- VERTOS MEDICAL INC raised $26M (Funding Round) on June 7, 2023.
- Bitterroot Bio raised $145M (Series A) on June 7, 2023.
- Candesant Biomedical, Inc. raised $35M (Series B) on June 6, 2023.
Who to call at Evommune, and when
A new round usually means Evommune is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Evommune raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Evommune, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Evommune. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Evommune raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansEvommune raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.